Pharmaceutical major Dr Reddy's Laboratories (DRL) will report its fourth-quarter earnings on Friday and analysts expect the company to post revenue growth of around 10 percent to Rs 3,886 crore.
- The street expects that EBITDA will improve this quarter all the way to 20.4 percent against 16.3 percent YoY with a profit at over Rs 400 crore.
- Revenue growth to be led by the US, India, Russia and emerging markets. Estimates are that the US could grow around 5 percent on QoQ basis. India growth could be seen at 10-13 percent.
- Commentary from the management will be important for DRL this time because the firm is one of the seven companies which have been named in the lawsuit with regards to price collusion in the US.